Skip Navigation

Cardiovascular Research 1997 35(1):99-105; doi:10.1016/S0008-6363(97)00089-8
© 1997 by European Society of Cardiology
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Regitz-Zagrosek, V.
Right arrow Articles by Fleck, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Regitz-Zagrosek, V.
Right arrow Articles by Fleck, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Angiotensin receptor type 1 mRNA in human right ventricular endomyocardial biopsies: downregulation in heart failure

Vera Regitz-Zagroseka,*, Jens Fielitza, R Dreyssea, Alfred G Hildebrandtb and Eckart Flecka

aInnere Medizin/Kardiologie, Virchow-Klinikum, Humboldt Universität and Deutsches Herzzentrum, Augustenburger Platz 1, 13353 Berlin, Germany
bBundesinstitut für Arzneimittel, Berlin, Germany

* Corresponding author. Tel.: +49 (30) 4593 1000; fax: +49 (30) 4593 2500; e-mail: regitz@ukrv.de

Received 8 November 1996; accepted 20 February 1997


   Abstract
Top
 Abstract
1 Introduction
 2 Methods
 3 Results
 4 Discussion
 References
 
Objective: Atrial angiotensin II receptors type 1 (AT1) are downregulated in end-stage human heart failure at mRNA and protein level. The present study investigated whether AT1 ventricular mRNA content was reduced in myocardial biopsies from heart failure patients. Methods: AT1 mRNA was quantitated in right ventricular endomyocardial biopsies from 16 patients with decreased left ventricular function (LVEF 36±3%) due to dilated cardiomyopathy (DCM) and in biopsies from 12 patients with suspected myocardial disease but normal cardiac function (LVEF 62±2%). Two biopsies per patient were pooled, RNA was extracted and reverse-transcribed after addition of an AT1 cRNA standard. AT1 standard and wild-type RNA were amplified with the same primers in the same PCR tube. The PCR products were hybridized to a microtiter plate and detected and quantitated by an ELISA system. Glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA was determined in the same samples as AT1 mRNA. Results: In the biopsies from 16 patients with heart failure, a 68% decrease in AT1 mRNA content was found in comparison with 12 controls (heart failure 94±15 AT1 mRNA copies/ng RNA; controls 297±45; P<0.001). Relating AT1 mRNA content to GAPDH mRNA confirmed the specific decrease in AT1 mRNA (AT1/GAPDH: heart failure 1.3±0.15; controls 3.4±0.5; P<0.002). The best correlation between AT1 mRNA content and clinical parameters was found for right ventricular ejection fraction (r = 0.59, P<0.01). Conclusions: The quantitative RT-PCR procedure indicated a loss of ventricular AT1 mRNA in human heart failure which corresponds to the loss of AT1 protein described previously. It may underlie the decrease in AT1 protein expression in human heart failure.

KEYWORDS Human; Angiotensin receptor; mRNA; RT-PCR


   1 Introduction
Top
 Abstract
 1 Introduction
2 Methods
 3 Results
 4 Discussion
 References
 
Cardiac angiotensin receptors (ATR) mediate the direct effects of angiotensin II (Ang II) on the heart. Cardiac Ang II effects probably play a role in remodelling after myocardial infarction, in the development of ventricular hypertrophy and in the morphological changes associated with heart failure. In the human heart, both ATR subtypes (AT1 and AT2) are expressed [1–3]. Ang II, via AT1, exerts hypertrophic and positive inotropic effects in the myocardium from experimental animals and in human atrial tissue [4–8]. In contrast, functions of AT2 are still largely unknown. In transfected rat vascular smooth muscle cells and rat coronary endothelial cells, antiproliferative effects of AT2 have recently been suggested [9, 10]and the induction of apoptosis by Ang II has been found in different cell lines which express abundant AT2 receptor [11]. This apoptotic function of AT2 may play a role in developmental biology and pathophysiology.

Regulation of cardiac AT1 has already been reported in a number of physiological conditions. Upregulation was found in hypertrophic and ischaemic states [12–14], whereas downregulation of cardiac AT1 was found in rat and human heart failure [1, 15, 16]. Human atrial and ventricular AT1 differ in expression level, which is higher in the atria [1, 17], and their effects on contractile function [8]. Whereas AT1 downregulation in human atria at end-stage heart failure has been well described at the mRNA and protein level, fewer data are available on ventricular AT1 regulation [1, 18, 19]. So far, ventricular AT1 regulation has only been investigated in explanted hearts from transplant recipients, which limits the conclusions to end-stage heart failure. To assess the regulation of human ventricular AT1 in heart failure of different stages, particularly in non-terminally-diseased patients, AT1 mRNA content must be assessed in endomyocardial biopsies. This approach has been used in the present study. A novel quantitative PCR procedure [20]enabled the determination of absolute mRNA copy numbers with a low variance. The study is the first to compare ventricular AT1 mRNA content in endomyocardial biopsies from patients with heart failure due to dilated cardiomyopathy and normal systolic cardiac function.


   2 Methods
Top
 Abstract
 1 Introduction
 2 Methods
3 Results
 4 Discussion
 References
 
AT1 mRNA was measured in endomyocardial biopsies from 16 patients with heart failure due to dilated cardiomyopathy undergoing diagnostic cardiac catheterization and right ventricular endomyocardial biopsy. All patients had decreased left ventricular function (mean LVEF 36±3%) and increased ventricular volumes in the presence of a normal left ventricular wall thickness (Table 1). Most patients belonged to the NYHA class II (n = 9), 5 to class III, 1 to class IV and 1 to class I. Patients were treated with digitalis (n = 9), ACE inhibitors (n = 14), and diuretics (n = 9). Twelve patients undergoing cardiac catheterization and biopsy for suspected myocarditis based on atypical chest pain, arrhythmia and/or borderline echocardiographic ventricular volumes and function who turned out to have normal right and left ventricular function at cardiac catheterization, without signs of inflammatory disease in the biopsy, were used as controls. These patients were treated with digitalis for supraventricular arrhythmia (n = 5) and with ACE inhibitors (n = 6) and/or diuretics (n = 3) for hypertension. Significant coronary artery disease was excluded by coronary angiography in all cases. Informed consent was obtained from all patients before tissue sampling. The study was approved by the Ethical Committee at the Virchow Clinic. The investigation conforms with the declaration of Helsinki.


View this table:
[in this window]
[in a new window]

  		Table 1 Patients studied—clinical and hemodynamic data

 
Cardiac catheterization in all patients included the measurement of left and right ventricular pressures, cardiac output, coronary angiography and the determination of right and left ventricular volumes and ejection fraction by biplane angiography after injection of 30 (right) or 40 (left) ml of non-ionic contrast medium. Volumes were determined according to the Simpson and Ferlinz method which were previously validated in our setting [21–23]. The left ventricular mass was calculated from the end-diastolic wall thickness in LAO projection and the left ventricular end-diastolic volume.

Right ventricular endomyocardial biopsies were taken at cardiac catheterization by a transfemoral approach using a 7-French Signus Bioptome (2.2 mmx104 cm, Signus GmbH, D-63755 Alzenau, Germany). The bioptome was directed versus the right ventricular septum by standard techniques. Two pieces were taken for histological (HE and van Giesson staining) and immunohistological examination and two were used for mRNA quantitation. Routine immunohistology included staining with antibodies for vimentin, alpha smooth muscle actin, panT-cells (UCL1), B-lymphocytes (CD21) and macrophages (KP1) (Dako, 22047 Hamburg, Germany). Patients with histological signs of myocarditis were excluded from the study.

Biopsies were frozen immediately on dry ice and stored at –70°C until analysis. Biopsies from controls and heart failure patients did not differ in wet weight (Table 2). Two biopsies per patient were pooled, RNA was extracted with RNAzol B (Lorei+Paesel, Germany) and subjected to a DNAse digest [20]. Yields of RNA before and after DNase digest were comparable in the patients with heart failure and controls. From each sample, 250 ng RNA were mixed with internal AT1 cRNA standard and reverse-transcribed with 300 ng random hexamers and 100 U SuperscriptTM (Gibco BRL, Germany). To control the efficient digestion of DNA, all samples were run after digestion in a PCR with the specific primers for AT1 (see below) before reverse transcription and with primers for pyruvate dehydrogenase (PDH) which yield bands of different length at the DNA and RNA level after reverse transcription [1]. All samples were negative for the AT1 and PDH DNA fragments, indicating complete digestion of DNA.


View this table:
[in this window]
[in a new window]

  		Table 2 Yield of RNA from endomyocardial biopsies before and after digestion with DNAseI

 
The construction of a 836 AT1 cRNA standard which differed from the corresponding AT1 wild-type mRNA only in a 6-base-pair deletion has been published previously [20]. The primer pair AT1-1/AT1-2 (AT1-1, 5'-CCTTCGACGCACAATGCTTG-3'; AT1-2, 5'-AGCCCTATCGGAAGGGTTGA-3') amplifies a 168 bp fragment containing the 6 bp deletion from the AT1 standard and a 174 bp fragment from the AT1 wild type. Amplification of standard and wild type in one tube with the primers AT1-1/AT1-2 produced the 168/174 fragments from standard and wild type with equal efficiency (Fig. 1a). For quantitation, 50 ng wild-type cDNA together with a given amount of standard was amplified in a 25 µl PCR assay with primers AT1-1 and AT1-2 [20]. Aliquots of PCR products were hybridized to different wells of a microtiter plate which bind specifically standard or wild type. This process was highly specific. Binding of standard amplicons to the wild-type capture probe reached only 0.3% of binding to the standard capture probe and binding of wild-type amplicons to the standard capture probe only 3% of the binding to the wild-type probe. For detection of bound amplicons, a digoxigenin molecule was integrated into the 5' end of primer AT1-2. The bound digoxigenin was quantitated with an anti-digoxigenin alkaline phosphatase conjugate in a 96-channel ELISA reader [20].


Figure 1
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Left panel: Amplification efficiency for the 168 bp fragment from AT1 standard and 174 bp fragment from wild type in a single PCR tube; 500 copies standard and wild type template were co-amplified in one tube. Aliquots were removed after 31, 32, 33, 34, 35, 36 and 37 cycles and the products were quantitated in the microtiter plates. Plotting specific ELISA-OD (optical density, x1000) against number of cycles in semilogarithmic manner shows identical efficiencies for standard and wild-type amplification. Right panel: Calculated ratios of wild-type/standard for the reverse transcription and co-amplification of increasing amounts of wild type RNA together with 40 000 copies standard in each tube. A linear increase in the ratios of wild-type/standard is observed over the whole measurement range.

 
About 40 000 copies of the standard cRNA were reverse-transcribed with 250 ng sample RNA. A regression line was established by adding the same amount of standard to increasing wild-type concentrations (50–1000 ng sample RNA). Over a relatively small measuring range, a linear increase in the wild-type/standard ratio resulted (Fig. 1b). Linearity is probably due to the high structural identity and thereby identical amplification efficiency of wild type and standard as well as to the fact that only a small measurement must be covered, since the changes in AT1 expression are relatively small. Based on this regression line and the known amount of standard in each sample, the amount of wild type was calculated. To ensure that potential changes in the AT1 mRNA were not due to mRNA degradation, the AT1 mRNA content in the atria and ventricles was related to the stably expressed GAPDH mRNA. The mRNA for GAPDH was amplified by PCR (22 cycles) and the amplicons were quantitated by HPLC.

To analyze the variability of the different steps of the procedure, 3 biopsies from about 10 mg were taken from an explanted heart. RNA was extracted from each sample, subjected to 3 different reverse transcriptions (RT, resulting in 9 different RTs) and each RT product was subjected to 3 different PCRs (27 PCRs) (Table 3). If one sample was reverse-transcribed in one RT, followed by 3 different PCRs, a mean PCR variability of about 10% resulted. If the 3 tissue samples were extracted and then reverse-transcribed in the same RT reaction (same master mixes and chemicals, identical conditions) and each of them was analysed by a single PCR, the variability between the different tissue samples (including the PCR variability) amounted to about 15%. If we reverse-transcribed each sample in 3 different RT's on 3 different days (with 3 different master mixes) and quantitated each RT product by a single PCR, variability amounted in the mean to 25%. This clearly indicates that the largest variance is introduced by the variability of the RT procedure. We reduced this variance in our study by reverse-transcribing all samples in a single RT using the same chemicals and master mixes.


View this table:
[in this window]
[in a new window]

  		Table 3 Variance for the quantitation of AT1 mRNA in ventricular biopsies

 
2.1 Statistics
Data are given as mean and s.e.m. Wilcoxon tests have been used to compare groups. In addition, confidence intervals for the mean values have been calculated using the SPSS programme. Pearson's correlation coefficients were calculated between AT1 expression and haemodynamic parameters.


   3 Results
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
4 Discussion
 References
 
Patients and controls differed significantly in ventricular AT1 mRNA expression. The number of AT1 copies amounted to 94±15 copies/ng RNA in the biopsies from failing hearts versus 297±45 (P<0.001) in the control group (Fig. 2), corresponding to a 68% loss of AT1 mRNA. 95% confidence intervals ranged from 208–385 copies/µg RNA in the control group and 64–123 copies/µg RNA in the heart failure group.


Figure 2
View larger version (37K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Number of AT1 mRNA copies in right ventricular endomyocardial biopsies from heart failure (HF) and from control patients (Con). AT1 mRNA is significantly decreased, by 68%, in heart failure. No significant difference in the GAPDH expression was found between both groups, whereas the AT1/GAPDH ratio was significantly decreased in the heart failure group, indicating the specificity of AT1 mRNA loss.

 
The mRNA for GAPDH was unchanged in heart failure and in controls (Fig. 2). If AT1 mRNA was related to GAPDH mRNA, the difference between controls and heart failure was maintained. The AT1/GAPDH ratio amounted to 1.3±0.15 in heart failure in comparison with 3.4±0.5 in controls (P<0.002, Fig. 2). Thus, relating AT1 expression to GAPDH expression confirmed the selective downregulation of AT1 mRNA.

Weak but significant correlations were detected between AT1 mRNA expression and right and left ventricular ejection fractions and volumes. The best correlation was found with right ventricular ejection fraction (r = 0.59, P<0.01), followed by left ventricular end-diastolic volume index (r = 0.48, P<0.02) and left ventricular ejection fraction (r = 0.43, P<0.05, Fig. 3). No correlation with left ventricular mass was detected (r = –0.042, P = 0.86, n.s.).


Figure 3
View larger version (10K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 Correlation between AT1 mRNA expression and right and left ventricular ejection fraction (RVEV, LVEF). Patients with DCM are depicted as circles and controls are depicted as squares. The number of AT1 copies is plotted against LVEF and RVEF and the equation of the regression line is indicated in the figure. Correlation coefficients are r = 0.43, P<0.05 for AT1/LVEF and r = 0.59, P<0.01 for AT1/RVEF. There is no significant correlation between LV- or RVEF and AT1 in the DCM group (LVEF/AT1, r = –0,30, P = 0.3, n.s.; RVEF, r = +0,40, P = 0.19, n.s.).

 
To determine whether AT1 downregulation was associated with medical therapy, we compared AT1 mRNA expression in the control group, where 6 patients were treated with ACE inhibitors and 6 were not. No significant difference was found (287±55 versus 306±52 copies/ng RNA).


   4 Discussion
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
References
 
Using a novel quantitative PCR technique, we determined the AT1 mRNA content in human right ventricular endomyocardial biopsies and found a significant (68%) decrease in AT1 mRNA in human heart failure. Relating AT1 mRNA to the mRNA of the stably expressed GAPDH mRNA confirmed the specific downregulation of ventricular AT1 in heart failure. AT1 mRNA content was significantly correlated with functional parameters of the right and left ventricle.

To determine the AT1 mRNA content, we used a quantitative RT-PCR procedure based on an internal AT1 cRNA standard, liquid-phase hybridization of PCR products to a 96-well microtiter plate and quantitation by an ELISA system [20]. The PCR-ELISA system has a low variance of about 10%, whereas a variance of about 25% is due to the combination of RT and PCR. The method allows for the determination of absolute copy numbers although limited by the assumptions that have to be made for calculations. Precise quantitation of the cRNA standard remains a problem that is inherent to most quantitative PCR approaches as well as the difficulty of ensuring that standard and wild type are reverse-transcribed with the same efficiency. The high structural similarity between standard and wild type including their surrounding DNA sequences favours similar transcription rates. For use in biopsies, we have optimized the RT procedure and the amount of standard to be added and we transcribed all samples in a single RT reaction.

To exclude non-specific degradation of mRNA, we related AT1 to GAPDH mRNA, confirming the selective downregulation of AT1 mRNA. GAPDH has already been used as a reference gene for mRNA quantitation in failing hearts and was found unchanged [24]. An increase in extracellular matrix proteins would not affect the results since the AT1 mRNA decrease is related to total RNA content and thus to the cellular components of the heart.

In different animal models of cardiac dysfunction, upregulation [13, 25]as well as downregulation [15]of ventricular AT1 has been described. Disease-dependent regulation of human myocardial AT1 has been studied by binding assays in atrial and ventricular membranes. Most investigators agree that the density of AT1 in the normal and failing human heart is low in comparison with β-adrenergic receptors and that AT1 is downregulated in heart failure [1, 2, 19]. Ventricular AT1 protein content has so far only been determined in explanted end-stage failing hearts, donor hearts or autopsy tissue, restricting conclusions to a narrow spectrum of pathophysiological conditions.

We have previously described a 60% loss of AT1 binding sites [1]and a 58% decrease of AT1 mRNA in the atria of end-stage failing hearts [20]. AT1 mRNA content has now been determined for the first time in right ventricular endomyocardial biopsies from heart failure patients with different degrees of functional impairment. The ventricular AT1 mRNa loss is comparable to the reduction in the atria. The higher expression of AT1 protein in the atria in comparison with the ventricles [1, 17]has now found its correspondence at the mRNA level since we determined 94 copies of AT1 mRNA/ng RNA in the failing ventricle whereas about double the number of copies was previously found in atria from heart failure patients [20]. These data suggest that changes in AT1 mRNA content correspond to changes in AT1 protein expression and that the reduced AT1 mRNA content may underlie the decreased AT1 protein expression.

The downregulation of cardiac AT1 mRNA may be caused by an increase in tissue Ang II content. Downregulation of AT1 by its agonist has already been described in glomerular mesangial cells [26]. Relevant cardiac Ang II levels may persist in heart failure in spite of ACE inhibitor therapy since cardiac ACE is upregulated [27]and not all ACE inhibitor dosages inhibit tissue ACE effectively over 24 h. Furthermore, human heart chymase may generate intracardiac Ang II, particularly in the presence of elevated Ang I concentrations, and thus may maintain relevant cardiac Ang II levels in spite of ACE inhibitor therapy [28]. Continuing action of chymase in the presence of ACE inhibitors may explain the lack of a correlation between AT1 expression and ACE inhibitor therapy.

The weak correlation between AT1 expression and clinical parameters is not surprising given the relatively small number of patients studied and the variance in medical therapy. The relatively small number of patients studied within each group together with the clustering of ejection fractions around the mean value in each group is probably the reason for the lack of a correlation between AT1 expression and ejection fraction within the control or DCM group. There was also no correlation with left ventricular mass or wall thickness, probably because all DCM patients had enlarged ventricles, in the presence of a normal wall thickness and the increase in mass reflected more the process of dilatation than hypertrophy. However, a significant correlation with right and also left ventricular ejection fraction was found, indicating a functional relevance of AT1-mediated effects in the human heart. Since we have used right ventricular endomyocardial biopsies and a decrease in right ventricular ejection fraction is a hallmark of the progression of dilated cardiomyopathy, the predominant correlation of AT1 expression with right ventricular ejection fraction seems reasonable.

The fact that we have used right ventricular endomyocardial biopsies to study a disease that is mainly characterized by left ventricular dysfunction represents somewhere a limitation of the study. However, biochemical changes in the right ventricular septum have already been shown to correlate with functional parameters of the left ventricle [29, 30].

A second limitation arises from the fact that AT2 mRNA was not quantitated. AT2 seems to play a role in developmental biology and may counteract AT1 in rat and mouse cell lines, in transfected vascular smooth muscle cells [9], neonatal rat myocytes [31], or rat coronary endothelial cells [10]. However, all cardiac actions of Ang II that have been revealed so far by subtype selective blockers in a number of intact animal models and in humans or have been found in the adult rodent or human heart are mediated by AT1. Therefore, we focused in the present clinical investigation first on AT1.

The consequences of the reduced AT1 expression in failing ventricles are still unknown. Ang II is coupled to calcium influx into cardiac myocytes. Downregulation of AT1 may thus prevent calcium loading of myocytes and act in a protective manner. Ang II, via AT1, exhibits positive inotropic actions in the normal human atrium but not in the failing ventricle [8]. Thus, downregulation of AT1 would not decrease contractility. Based on recent data from rat heart, downregulation of AT1 may limit specific growth responses [32, 33]and thereby prevent a progression of hypertrophy. In vascular smooth muscle cells, Ang II, via AT1, elicits contraction and hyperplasia. The reduction of such an effect could be beneficial in a number of pathophysiological states. However, further investigations must be awaited to clarify this issue.

Time for primary review 25 days.


   Acknowledgements
 
We thank Dr. E. Wellnhofer for his advice in the quantitative evaluation of right and left ventricular angiograms. We appreciate the excellent technical assistance of Heike Kallisch and Britta Hannack. The study was supported by DFG Re662/2-2.


   References
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 References
 

  1. Regitz-Zagrosek V., Friedel N., Heymann A., et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation (1995) 91:1461–1471.[Abstract/Free Full Text]
  2. Nozawa Y., Haruno A., Oda N., et al. Angiotensin II receptor subtypes in bovine and human ventricular myocardium. J Pharmacol Exp Ther (1994) 270:566–571.[Abstract/Free Full Text]
  3. DeGasparo M., Rogg H., Brink M., et al. Angiotensin II receptor subtypes and cardiac functions. Eur Heart J (1994) 15(suppl_D):98–103.
  4. Koch-Weser J. Myocardial actions of angiotensin. Circ Res (1964) 14:337–344.[Abstract/Free Full Text]
  5. Fowler N.O., Holmes C.J. Coronary and myocardial actions of angiotensin. Circ Res (1964) 14:191–201.[Abstract/Free Full Text]
  6. Khairallah PA, Kanabus J. Angiotensin and myocardial protein synthesis. In: Tarazi RD, Dunbar JB, editors. Perspectives in cardiovascular research, vol 8. New York: Raven Press, 1983:337–347.
  7. Baker K.M., Booz G.W., Dostal D.E. Cardiac actions of angiotensin II: role of an intracardiac renin–angiotensin system. Annu Rev Physiol (1992) 54:227–241.[CrossRef][Web of Science][Medline]
  8. Holubarsch C., Hasenfuss G., Schmidt-Schweda S., et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. Circulation (1993) 88:1228–1237.[Abstract/Free Full Text]
  9. Nakajima M., Huchtinson H.G., Fujinaga M., et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA (1995) 92:10663–10667.[Abstract/Free Full Text]
  10. Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest (1995) 95(2):651–657.[Web of Science][Medline]
  11. Yamada T., Horiuchi M., Dzau V. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA (1996) 93:156–160.[Abstract/Free Full Text]
  12. Lambert C., Massillon Y., Meloche S. Upregulation of cardiac angiotensin II AT1 receptors in congenital cardiomyopathic hamsters. Circ Res (1995) 77:1001–1007.[Abstract/Free Full Text]
  13. Suzuki J., Matsubara H., Urakami M., Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res (1993) 73:439–447.[Abstract/Free Full Text]
  14. Meggs L.G., Coupet J., Huang H., et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res (1993) 72:1149–1162.[Abstract/Free Full Text]
  15. Lopez J.J., Lorell B.H., Ingelfinger J.R., et al. Distribution and function of cardiac angiotensin AT1 and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol (1994) 36:H844–H852.
  16. Rogg H., DeGasparo M., Graedel E., et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J (1996) 17:1112–1120.[Abstract/Free Full Text]
  17. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husian A. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab (1989) 69:54–66.[Abstract/Free Full Text]
  18. Haywood G.A., Gullestad L., Katsuya T., et al. Angiotensin II receptor subtypes in failing and non-failing human hearts: analysis of gene expression (Abstract). J Am Coll Cardiol (1996) 27(suppl A):978–996.[CrossRef][Web of Science][Medline]
  19. Asano K., Minobe W., Mitchusson K., et al. Selective downregulation of angiotensin II AT1 receptors in failing human heart: relationship to β1-receptor downregulation (Abstract). J Am Coll Cardiol (1995) 25:291.
  20. Bauer P., Regitz-Zagrosek V., Hofmeister J., et al. Reduced atrial angiotensin receptor type 1 mRNA content in end-stage heart failure—validation of a novel quantitative PCR-ELISA technique. J Mol Med (1996) 74:447–454.[CrossRef][Web of Science][Medline]
  21. Chapmann C., Baker O., Reynolds J., Bonte F. Use of biplane cinefluorography for measurement of ventricular volume. Circulation (1958) 18:1105–1114.[Web of Science][Medline]
  22. Ferlinz J., Gorlin R., Cohn P., Herman M. Right ventricular performance in patients with coronary artery disease. Circulation (1975) 52:608–613.[Abstract/Free Full Text]
  23. Beier J., Wellnhofer E., Oswald H., Fleck E. Accuracy and precision of angiographic volumetry methods for left and right ventricle. Int J Cardiol (1996) 53:179–188.[CrossRef][Web of Science][Medline]
  24. Ungerer M., Böhm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation (1993) 87:454–463.[Abstract/Free Full Text]
  25. Reiss K., Capasso J.M., Huang H.E., Meggs L.G., Li P., Anversa A. ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure. Am J Physiol (1993) 264:760–767.
  26. Makita N., Iwai N., Inagami T., Badr K.F. Two distinct pathways in the down-regulation of type-1 angiotensin II (AII) receptor gene in rat glomerular mesangial cells. BBRC (1992) 185:142–146.[Medline]
  27. Studer R., Reinicke H., Müller B., Holtz J., Just H., Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest (1994) 94:301–310.[Web of Science][Medline]
  28. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A. Identification of a highly specific chymase as the major angiotensin II forming pathway in the human heart. J Biol Chem (1990) 265:22348–22357.[Abstract/Free Full Text]
  29. Peters T., Wells G., Oakley C., et al. Enzymic analysis of endomyocardial biopsy specimens from patients with cardiomyopathies. Br Heart J (1977) 39:1333–1339.[Abstract/Free Full Text]
  30. Regitz V., Shug A.L., Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol (1990) 65:755–760.[CrossRef][Web of Science][Medline]
  31. Booz G.W., Baker K.M. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension (1996) 28:635–640.[Abstract/Free Full Text]
  32. Schunkert H., Weinberg E.O., Bruckschlegel G., Riegger A.J.G., Lorell B.H. Alterations of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. J Clin Invest (1995) 96:2768–2774.[Web of Science][Medline]
  33. Schunkert H., Sadishima J., Cornelius T., et al. Angiotensin II-induced growth responses in isolated adult rat hearts. Circ Res (1995) 76:489–497.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. W. Adams, J. Wang, J. R. Davis, C. Liaw, I. Gaidarov, J. Gatlin, N. D. Dalton, Y. Gu, J. Ross Jr., D. Behan, et al.
Myocardial expression, signaling, and function of GPR22: a protective role for an orphan G protein-coupled receptor
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H509 - H521.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. Maczewski, M. Borys, P. Kacprzak, T. Gdowski, and D. Wojciechowski
Angiotensin II AT1 receptor density on blood platelets predicts early left ventricular remodelling in non-reperfused acute myocardial infarction in humans
Eur J Heart Fail, March 1, 2006; 8(2): 173 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
J. L Mehta and Dayuan Li
Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S70 - S76.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Regitz-Zagrosek, V.
Right arrow Articles by Fleck, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Regitz-Zagrosek, V.
Right arrow Articles by Fleck, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?